1. FDA places a full clinical hold on HCB301 after serious haematologic adverse events
FBD Biologics, a subsidiary of a Taiwan-listed company, disclosed in a stock exchange filing on 18 November that FDA has placed a full clinical hold on the IND for HCB301, a trispecific fusion protein acting on the CD47/SIRPα, PD-L1 and TGF-β pathways that is in Phase 1 in advanced solid tumours and relapsed or refractory classical Hodgkin lymphoma. According to the filing, the decision was based on accumulated safety data including serious haematologic adverse events, and the company has suspended enrolment and dosing while continuing safety follow-up of participants. The company says it is studying the mechanism of the thrombocytopenia and evaluating papaverine as a possible mitigation, while stating that a causal relationship with platelet recovery and any preventive effect have not been established. For safety teams, cytopenias are a recognised class concern with CD47-targeting agents, and the case shows why haematologic monitoring, clear dose-modification rules and timely aggregate review of related events need to be in place from first-in-human onwards. FBD Biologics filing via MoneyDJ, 18 Nov 2026
2. Marstacimab (Hympavzi) now carries a boxed warning for thromboembolic events
FDA approved on 6 November a safety labelling change adding a boxed warning to Hympavzi (marstacimab-hncq), the anti-TFPI antibody used as haemophilia A or B prophylaxis: venous and arterial thromboembolic events have been reported in patients with thrombotic risk factors, and treatment should be interrupted if signs or symptoms occur. The updated Warnings and Precautions section reports such events in 0.8% of patients (2/259) in the open-label extension study, including one patient with inhibitors who died of complications of a post-surgical cerebral infarction, and notes postmarketing reports. Pfizer's letter to providers, published by the Hemophilia Federation of America on 17 November, says the US prescribing information was updated on 9 November. For safety teams working with haemostatic rebalancing agents, the change underlines the need to capture thrombotic risk factors, surgery and concomitant factor use in case reports, and to manage peri-operative and acute-illness periods carefully. FDA, 6 Nov 2026 and Hemophilia Federation of America, 17 Nov 2026
3. EU: DHPC on Caelyx vials whose seal and stopper may detach
EMA published on 17 November a DHPC from Baxter on Caelyx (pegylated liposomal doxorubicin) 50 mg/25 mL vials, after reports of improperly crimped aluminium seals in specific batches. Removing the flip-off cap may cause the seal and rubber stopper to detach, leaving the vial open, compromising sterility and risking unintended occupational exposure to the cytotoxic product. Healthcare professionals are asked to inspect each vial before use and again after cap removal, not to use any vial with a visible defect and to contact Baxter; vials without visible defects may be used. Baxter considers the overall risk low because the defect is readily visible and reports no related adverse events to date, but safety teams should watch for infections after administration and occupational exposure reports linked to the affected lots, which differ by country. EMA, 17 Nov 2026
4. FDA launches EAST to test more marketed drugs, as ANSM recalls a nifedipine lot after laboratory testing
FDA announced on 18 November its Enhanced Approach for Sampling and Testing (EAST), which combines rapid screening methods with traditional testing to sample more drugs bought from retail pharmacies and wholesale distributors, across more manufacturers, therapeutic classes and regions in the US and abroad. Testing focuses on identity, purity and potency, samples flagged by screening undergo confirmatory testing with validated methods such as USP methods, and results will inform regulatory action and inspection planning. On the same day, France's ANSM published a recall, at hospital level, of one lot (008825) of Mapakna LP 20 mg prolonged-release nifedipine tablets after its control laboratories found non-compliant dissolution results, with no related quality complaints or pharmacovigilance cases reported so far. For safety teams, broader regulator testing means more quality findings are likely to emerge on marketed products, and reports of lack of efficacy or unexpected toxicity should be reviewed against known quality issues for the lots concerned. FDA, 18 Nov 2026 and ANSM, 18 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles